The Role of Molecular Tests in Acute Myelogenous Leukemia Treatment Decisions
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The prognosis for patients with acute myelogenous leukemia (AML) is dependent on age, karyotype, and the genetics of the neoplastic cell. The molecular markers with prognostic impact include mutations in FLT3, NPM1, MLL, WT1, c-KIT, and expression levels of BAALC, NM1, ERG, and CXCR4. Gene expression profiles and microRNA expression patterns in AML may prove highly useful in defining the prognosis of AML. Cytogenetic and, increasingly, molecular findings are used in determining the best therapy for AML patients, especially the choice of whether to perform allogeneic stem cell transplantation.
KeywordsAcute myeloid leukemia Genetics Prognosis FLT3 NPM1
- The Role of Molecular Tests in Acute Myelogenous Leukemia Treatment Decisions
Current Hematologic Malignancy Reports
Volume 5, Issue 2 , pp 109-117
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Acute myeloid leukemia
- Industry Sectors